Compare +50 FDA De Novo Providers: How to Choose the Right Team in 2026

If your device has no valid predicate and you are planning a De Novo request, provider quality directly affects timeline, study scope, and reviewer confidence. This page gives you a practical, evidence-first model to compare providers without relying on sales claims alone.

Why De Novo Provider Selection Is Different from Standard 510(k)

De Novo is a classification request pathway used when a device is novel and low to moderate risk, and no suitable Class I/II predicate exists. Unlike many 510(k) projects where teams can anchor to prior cleared templates, De Novo strategy often begins with uncertainty around classification, special controls, and minimum evidence needed to support reasonable assurance of safety and effectiveness. Provider teams that perform well in this setting usually combine regulatory writing, risk analysis, test strategy, and strong pre-submission communication discipline.

FDA’s De Novo framework has specific procedural and content expectations. Teams must align indications, technological narrative, nonclinical evidence, labeling, and risk mitigations into a coherent benefit-risk package. If your provider treats De Novo like a renamed 510(k), you usually see preventable cycles: weak problem statement framing, insufficient risk-to-control traceability, and delayed updates after agency feedback. The right provider helps your internal team make fewer expensive turns by defining assumptions early, documenting decisions, and building an integrated evidence map before major spend starts.

What High-Quality De Novo Providers Actually Do

Provider Scoring Framework (0-100)

Use this weighted framework to compare at least three providers. Ask for direct examples from completed De Novo programs and verify who did the work. A provider with polished proposals but weak execution ownership is a common failure mode.

How to Run the RFP Process in 30 Days

Most teams can complete first-pass provider evaluation in four weeks if they keep scope disciplined. Start by documenting device concept, intended use, user environment, and known risk profile. Then publish a short request package asking each provider for: (1) pathway rationale outline, (2) top evidence gaps, (3) draft timeline with assumptions, (4) team composition, and (5) pricing logic tied to milestones.

In Week 1, circulate your background packet and require written Q&A in a single channel. In Week 2, host working sessions where providers explain how they would decide what is in-scope versus optional evidence. In Week 3, score written deliverables using the framework above. In Week 4, run reference checks with at least two former clients whose programs had meaningful complexity. Choose the team that gives the strongest decision-quality process, not only the fastest promise.

Questions to Ask Every De Novo Provider

• check_circle
  Which De Novo submissions did your core team personally lead in the last 24 months?
• check_circle
  How do you convert hazard analysis into a prioritized evidence matrix?
• check_circle
  What triggers a recommendation for early Q-Submission versus direct filing prep?
• check_circle
  How do you manage software updates or requirement changes during dossier drafting?
• check_circle
  What assumptions drive your estimate, and what changes would increase cost?
• check_circle
  What will my internal team own weekly so we do not lose knowledge post-submission?

Build an Internal Decision Memo Before You Sign

A short internal decision memo prevents common procurement mistakes. Capture your chosen provider, top alternatives, weighted scores, and major assumptions. Include a summary of the first 90 days: expected outputs, owners, and measurable milestones. If leadership asks why this provider was selected, you can point to evidence-based reasoning instead of preference. This also makes performance management cleaner if scope drifts.

The highest-value memo sections are: expected evidence package by milestone, reviewer-risk assumptions, and escalation thresholds. Define what constitutes a material issue requiring leadership attention, such as missed response targets, unresolved critical test design disputes, or quality-system integration blockers. A provider partnership works best when both sides agree on decision rights and escalation speed before pressure increases.

How Cruxi Helps You Compare Providers More Objectively

Cruxi does not replace your provider search. It helps your team evaluate proposals consistently by structuring assumptions, timeline drivers, and evidence requirements in tools your team can reuse. Start with the readiness model to baseline your current state, then stress-test duration and budget assumptions against your expected evidence profile.

Decision-Quality Signals from Provider Workshops

The most useful provider workshop output is not a polished slide deck. It is a transparent reasoning chain that your team can test. Ask each provider to walk through one representative high-risk claim and explain exactly how they would: define decision criteria, choose evidence type, set acceptance bounds, and pre-empt likely reviewer concerns. If the logic is clear, your team should be able to identify where assumptions are strong and where uncertainty remains. If the provider cannot make this chain explicit, later project governance usually becomes reactive.

Capture each workshop in a structured template with the same fields for every candidate: assumptions used, open questions, risks they flagged, and choices they deferred. Consistency in note-taking prevents bias toward presentation style and keeps the decision anchored in comparable content. This also helps when leadership asks why one team was selected over another. You can point to concrete differences in execution logic and risk control, not subjective confidence.

How to Prevent Scope and Pricing Friction After Selection

Many teams finalize provider selection correctly, then lose value during contracting because assumptions are not written into milestones. Avoid this by translating top assumptions into contract language. Example: if your timeline assumes one Q-Submission interaction and no additional major protocol redesign, state those assumptions explicitly in the scope and define change-order triggers. Clarity here reduces both commercial friction and delivery delays.

Define three governance rules in writing. Rule one: every major decision has a named owner and due date. Rule two: unresolved issues above a defined impact threshold escalate within a fixed window. Rule three: every submission-critical artifact has version control and acceptance criteria. These controls are simple, but they prevent the common pattern where teams discover late that external and internal working assumptions never matched.

References

The framework on this page reflects publicly available FDA and standards-facing guidance used in De Novo planning:

• FDA: De Novo Classification Request
• 21 CFR Part 860, Subpart D (De Novo Classification)
• FDA Q-Submission Program Guidance
• FDA Benefit-Risk Factors Guidance (context for decision framing)
• FDA Software Documentation in Premarket Submissions